provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
HomeHealth TopicMental Health

Can MDMA Treat Depression and Anxiety?

Arielle Tandowski, MPHMandy Armitage, MD
Updated on May 1, 2025

Key takeaways:

  • MDMA is an illegal, synthetic drug that causes increased energy, pleasure, and self-awareness.

  • MDMA-assisted therapy (MDMA-AT) is only available in some states and in very specific situations. When combined with talk therapy, it may be helpful for certain mental health conditions, like post-traumatic stress disorder (PTSD) and social anxiety in people with autism.

  • More research is needed to understand whether MDMA-AT could be helpful for treating other kinds of anxiety and depression. 

Woman sitting on the ground feeling anxious.
valentinrussanov/E+ via Getty Images

You may have heard of MDMA (3,4-methylenedioxy-methamphetamine). It’s a psychedelic drug that goes by many other names, including “molly” and “ecstasy.” MDMA can increase energy and feelings of happiness, empathy, openness, and social connection. It can also cause serious side effects, like a dangerous increase in body temperature. 

Even though MDMA is illegal today, it was once used as a psychotherapy tool back in the 1970s. While it showed benefits in psychotherapy, MDMA got a bad reputation when it became a popular recreational drug. By 1985, it became illegal in most countries. 

After that, MDMA-assisted therapy (MDMA-AT) could only be used legally as part of a clinical trial.

Search and compare options

Search is powered by a third party. By clicking a topic in the advertisement above, you agree that you will visit a landing page with search results generated by a third party, and that your personal identifiers and engagement on this page and the landing page may be shared with such third party. GoodRx may receive compensation in relation to your search.

Since then, researchers have taken a renewed interest in psychedelic-assisted therapy. Strong research supports MDMA-AT for people with post-traumatic stress disorder (PTSD). But what about using it as treatment for other mental illnesses? Here’s what the science says about MDMA-AT for depression and anxiety.

How does MDMA work for depression and anxiety?

Most of the research on MDMA-AT has focused on people with PTSD. There hasn’t been as much research on using MDMA to treat depression and anxiety. But scientists believe it might help in different ways. 

MDMA boosts the activity of certain chemical messengers in your brain and body, including:

MDMA also affects activity in areas of your brain that control mood, emotions, and memory. It may also help your amygdala and hippocampus (the brain’s memory center) communicate better

Because of these effects, MDMA might make it easier to talk about stress and trauma or to reprocess painful memories. It could also help with:

  • A positive mood and lower stress levels

  • Being less defensive when talking about difficult experiences

  • Trusting and opening up to others

  • Seeing problems in a new way

  • A better ability to remember and confront memories

  • Understanding emotional and social relationships better

GoodRx icon
  • Psilocybin for depression: Most research on psilocybin (a substance found in certain mushrooms) is in people with depression. So far, the results are showing positive effects.

  • Ketamine and depression: Ketamine has been used for different things over the decades, but there’s growing research on ketamine as a treatment for depression.

  • Adaptogens and anxiety: These plant-based treatments may help with mood disorders in some people. Here’s what you need to know about them.

But recreational MDMA use can sometimes cause anxiety, depression, or panic attacks — especially in the days or weeks after using it. This is sometimes called the “mid-week blues.” It’s not clear if MDMA itself causes these problems, or if other things — like contamination, dosage, or multiple substance use — are to blame. 

So far, most research on MDMA-AT for anxiety and depression has focused on two groups of people: people with end-of-life anxiety and people with autism who have social anxiety. More research is needed to understand if the benefits can apply to wider populations.

Can MDMA help social anxiety?

Maybe — but the research is limited. One trial using 2 sessions of MDMA-AT found that it led to less social anxiety in people with autism at 6 months. But this study was very small — it only included 12 people. And there hasn’t been any published research to support these results since.

Theories of why MDMA might be helpful for social anxiety include:

  • MDMA might help people change how they feel about negative memories, especially memories about themselves or relationships with others.

  • MDMA may be able to promote positive emotions, including toward yourself.

  • MDMA may reduce fear in social situations and help people feel more connected to others.

Can MDMA help end-of-life anxiety?

Nearly half of people with a life-limiting illness feel anxiety or depression. Palliative care experts are looking into newer ways to help, including psychedelics like MDMA. 

One study suggests MDMA-AT may help ease anxiety related to life-threatening illness or help people who are dying find a sense of meaning and purpose. But more research is needed to say for sure how well this works.

What does MDMA-assisted therapy (MDMA-AT) for depression look like?

MDMA-AT is talk therapy combined with MDMA. When researchers do MDMA-AT with study participants, they follow special guidelines. These guidelines, created by the Multidisciplinary Association for Psychedelic Studies (MAPS), are based on methods created by therapists who studied MDMA before it became illegal. 

Let’s take a look at what that process looks like.

Preparatory session(s)

These sessions lay the groundwork for the MDMA-AT process. They might include:

  • Medical screening to be sure MDMA use is safe

  • A meeting between the therapist and participant to establish a relationship, create a safe physical and mental environment, and set goals 

  • Education about the possible physical and psychological effects of MDMA

Participants may have more than one preparatory session. They move to the next step when both the participant and therapist feel ready. 

MDMA-assisted session

The MDMA-assisted session begins with the study participant taking a capsule of MDMA. The full session lasts several hours. Sometimes participants stay overnight at the clinic or with informed friends or family.

During the session, participants sit or lie down in a comfortable room. They wear eye shades and headphones with a preset music playlist. Music is often used in psychedelic therapy and is shown to help improve the experience and outcome of the session. 

The session may alternate between periods of introspection (thinking to oneself) and periods of interaction with the therapists. A therapist or other facilitator stays with the participant at all times.

Everyone’s personal experience will be different, and sometimes the session may be challenging. During the session, people may:

  • See and hear things differently (like brighter, louder, or clearer for example)

  • Rethink aspects of their lives from a new perspective

  • Feel like they’re reliving or reexperiencing past moments

  • Feel less fear

  • Talk more openly about thoughts or memories that cause anxiety or depression.

Therapists don’t lead or guide the session. Instead, they:

  • Listen and encourage trust 

  • Ensure participant safety

  • Take notes or recordings to help participants recall their experiences

Integration

After the session, the participant and therapist(s) work together to make sense of the experience. The outcome may not be clear right away. That’s because the psychedelic experience can be confusing and hard to describe.

There are many definitions of integration. In general, this is the process of taking lessons or insights from the session and using them in everyday life. This process usually involves methods of talk therapy. Different models of integration focus on:

  • Spiritual growth

  • Relationships

  • Self-reflection

  • The body or nature 

A range of practices may be part of the process, like exercise, meditation, healthier habits, or art therapy. 

The number of sessions for each step may vary. For example, in the MAPS research program, there are two MDMA sessions (separated by a month), three preparatory sessions, and three or four integration sessions before and after each MDMA session. 

What are the risks of MDMA?

MDMA comes with risks, and some of them can be life-threatening. Soon after taking MDMA, you may develop:

  • Large, dilated pupils

  • Uncontrollable clenching of your jaw

  • Nausea and decreased appetite

  • Tingling sensation in your arms or legs

  • Faster heart rate

  • Elevated blood pressure

  • Difficulty concentrating or remembering things

  • Difficulty balancing

More serious side effects of MDMA use include:

  • Overheating: A fast rise in body temperature can occur, especially in a warm environment like a dance club. When it happens, it’s often fatal.

  • Harm to your organs: Heart problems (like an abnormal rhythm or heart attack) and liver damage may occur after taking MDMA.

  • Death: Although rare, overdoses leading to death are possible. This is more likely when taken recreationally because of contamination or dangerous interactions with other recreational or prescription medicines.

Is MDMA addictive?

It’s unclear if MDMA is addictive. Some people report continued use of MDMA despite negative side effects. Others need more of it over time to feel the same positive result. But a small study suggested MDMA-AT may help treat alcohol use disorder. In addition to lower alcohol consumption, people reported no interest in using illegal MDMA after their sessions.

Does MDMA damage the brain?

It’s unclear if MDMA causes long-term brain damage. In animal studies, MDMA has toxic effects on nerve cells in the brain. A review paper concluded that people who repeatedly use MDMA experienced changes in brain function and cognition. It’s possible that these changes may be reversed over time when a person no longer uses MDMA. But the long-term effects haven’t been adequately studied. 

Theoretically, risks might be lower in MDMA-AT. That’s because the doses are small, and the number of sessions are limited. But it’s impossible to say for sure.

Is MDMA-AT safer than MDMA?

Yes, MDMA-AT is likely safer than recreational use because:

  • People go through a medical screening to make sure participation is safe. 

  • The dose and purity of MDMA are carefully monitored. 

  • Healthcare professionals are present to make sure participants are safe. 

What drugs interact with MDMA?

It’s risky to combine MDMA with other drugs or medications. Avoid taking MDMA in combination with:

  • Antidepressants: Commonly prescribed antidepressants include selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs). Combining MDMA with SSRIs or MAOIs can lead to “serotonin syndrome” — a dangerous and often deadly condition. Bupropion is a norepinephrine/dopamine-reuptake inhibitor (NDRI) that, when combined with MDMA, increases blood levels of both substances, making overdose more likely.

  • Amphetamines and stimulants: Cocaine or stimulant medications like methylphenidate (often used to treat ADHD) can cause a dangerous increase in heart rate when combined with MDMA.

  • Alcohol: Mixing alcohol with MDMA may be dangerous because it increases the risk of dehydration and low sodium levels.

  • Opioids, anesthetics like ketamine, and muscle relaxers: These increase the risk of death when mixed with MDMA.

The bottom line

Experts don’t know enough about MDMA yet to say for sure if it can treat anxiety or depression. But there’s some evidence that MDMA-AT might be helpful for people with PTSD and certain types of anxiety. These same benefits might also help more people with anxiety or depression, but more research is needed to confirm this. 

Right now, MDMA isn’t approved for any medical use. As researchers learn more about MDMA-AT, they’ll be able to better understand its role in mental health treatment. 

why trust our exports reliability shield

Why trust our experts?

Arielle Tandowski, MPH
Arielle Tandowski, MPH, is a freelance writer for GoodRx. She holds a master's degree in public health from the University of Haifa, where she focused on mental health, substance use, and harm reduction.
Katie E. Golden, MD
Katie E. Golden, MD, is a board-certified emergency medicine physician and a medical editor at GoodRx.
Mandy Armitage, MD
Reviewed by:
Mandy Armitage, MD
Mandy Armitage, MD, has combined her interests in clinical medicine with her passion for education and content development for many years. She served as medical director for the health technology companies HealthLoop (now Get Well) and Doximity.

DISCLAIMER: MDMA-AT is only legal in some states when used as part of a government-approved clinical trial under limited circumstances, but not in others. MDMA is still illegal under federal law.

View All References (37)

Cajanding, R. J. M. (2019). MDMA-associated liver toxicity: Pathophysiology, management, and current state of knowledge. AACN Advanced Critical Care.

Carhart-Harris, R. L., et al. (2014). The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level–dependent resting state functional connectivity. Biological Psychiatry

Cohen, I. V., et al. (2021). Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Scientific Reports

Conner, K. M. (2023). Everything old becomes new again: Five things to know about psychedelics in palliative care. EBSCO.

Danforth, A. L., et al. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology

Dobry, Y., et al. (2013). Ecstasy use and serotonin syndrome: A neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. International Journal of Adolescent Medicine and Health

Docherty, J. R., et al. (2021). Cardiovascular and temperature adverse actions of stimulants. British Journal of Pharmacology.

Dunlap, L. E., et al. (2018). Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine (MDMA). ACS Chemical Neuroscience.

Endocrine Society. (2022). Adrenal hormones

Feduccia, A. A., et al. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Fineberg, S. K., et al. (2016). Oxytocin and the social brain. Biological Psychiatry

Gillman, P. K. (2017). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia.

Greer, G. R., et al. (1998). A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs.

Halpern, J. H., et al. (2010). Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction

Johansen, P., et al. (2009). How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology

Johnson, M. W., et al. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology

Kaelen, M., et al. (2018). The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology

Kozlov, E., et al. (2019). Prevalence, severity, and correlates of symptoms of anxiety and depression at the very end of life. Journal of Pain and Symptom Management.

Luoma, J. B., et al. (2021). Potential processes of change in MDMA-assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships. Human Psychopharmacology: Clinical & Experimental

Mithoefer, M. C., et al. (2017). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. Multidisciplinary Association for Psychedelic Studies. 

Montgomery, C., et al. (2021). Neurological and cognitive alterations induced by MDMA in humans. Experimental Neurology.

Multidisciplinary Association for Psychedelic Studies. (n.d.). Expanded access program for MDMA-assisted therapy for patients with treatment-resistant PTSD (EAMP1).

Multidisciplinary Association for Psychedelic Studies. (2010). Accounts of MDMA’s effects

Mustafa, N. S., et al. (2020). MDMA and the brain: A short review on the role of neurotransmitters in neurotoxicity. Basic and Clinical Neuroscience

National Institute on Drug Abuse. (2024). MDMA (ecstasy/molly). National Institutes of Health. 

O’Brien, S., et al. (2025). MDMA-assisted therapy: Challenges, clinical trials, and the future of MDMA in treating behavioral disorders. CNS Spectrums

Passie, T. (2018). The early use of MDMA (‘ecstasy’) in psychotherapy (1977–1985). Drug Science, Policy and Law

Patel, R., et al. (2015). MDMA for the treatment of mood disorder: All talk no substance? Therapeutic Advances in Psychopharmacology

Regan, A., et al. (2021). Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis. PloS One

Sarparast, A., et al. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: A systematic review. Psychopharmacology

Sessa, B., et al. (2019). A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Frontiers in Psychiatry

Sessa, B., et al. (2021). First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology

Sessa, B., et al. (2022). Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA. Journal of Psychopharmacology

The New York Times. (1985). U.S. will ban ‘ecstacy,’ a hallucinogenic drug

Tullis, P. (2021). How ecstasy and psilocybin are shaking up psychiatry. Nature. 

van Amsterdam, J., et al. (2021). Hard boiled: Alcohol use as a risk factor for MDMA-induced hyperthermia: A systematic review. Neurotoxicity Research.

Wolfgang, A. S., et al. (2024). MDMA and MDMA-assisted therapy. The American Journal of Psychiatry.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

For additional resources or to connect with mental health services in your area, call SAMHSA’s National Helpline at 1-800-662-4357. For immediate assistance, call the National Suicide Prevention Lifeline at 988, or text HOME to 741-741 to reach the Crisis Text Line.

Was this page helpful?

Habits for a Healthier Mind

Sign up for our GoodRx Mental Well-being Newsletter to receive up-to-date information on the latest medications, tips, and savings that are most relevant to you.

By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.